Ryan J. Hartmaier

5.7k total citations · 4 hit papers
63 papers, 2.1k citations indexed

About

Ryan J. Hartmaier is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Ryan J. Hartmaier has authored 63 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 29 papers in Cancer Research and 27 papers in Oncology. Recurrent topics in Ryan J. Hartmaier's work include Lung Cancer Treatments and Mutations (36 papers), Cancer Genomics and Diagnostics (26 papers) and Colorectal Cancer Treatments and Studies (13 papers). Ryan J. Hartmaier is often cited by papers focused on Lung Cancer Treatments and Mutations (36 papers), Cancer Genomics and Diagnostics (26 papers) and Colorectal Cancer Treatments and Studies (13 papers). Ryan J. Hartmaier collaborates with scholars based in United States, United Kingdom and South Korea. Ryan J. Hartmaier's co-authors include Juliann Chmielecki, Jeffrey S. Ross, Steffi Oesterreich, Ethan Sokol, Laurie M. Gay, Nikita Pozdeyev, Daniel W. Bowles, Lauren Fishbein, Stephanie Davis and Aik Choon Tan and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Ryan J. Hartmaier

60 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers

2018 374 citations Nikita Pozdeyev, Laurie M. Gay et al. Clinical Cancer Research profile →
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

2023 130 citations Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications profile →
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

2022 95 citations Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery profile →
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

2023 95 citations Juliann Chmielecki, Tony Mok et al. Nature Communications profile →

Peers

Countries citing papers authored by Ryan J. Hartmaier

Since Specialization

Citations

This map shows the geographic impact of Ryan J. Hartmaier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan J. Hartmaier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan J. Hartmaier more than expected).

Fields of papers citing papers by Ryan J. Hartmaier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan J. Hartmaier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan J. Hartmaier. The network helps show where Ryan J. Hartmaier may publish in the future.

Co-authorship network of co-authors of Ryan J. Hartmaier

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan J. Hartmaier. A scholar is included among the top collaborators of Ryan J. Hartmaier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan J. Hartmaier. Ryan J. Hartmaier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib 2024 ·Lung Cancer ·Colin R. Lindsay, (unknown), (unknown), Nan Jia, Ryan J. Hartmaier, Shun Lü	1
2	Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Thomas John, Christian Grohé, Jonathan W. Goldman, Terufumi Kato, К. К. Лактионов, Laura Bonanno, Marcello Tiseo, Margarita Majem, Manuel Dómine, Myung‐Ju Ahn, M. Pérol, Ryan J. Hartmaier, Jacqulyne Robichaux, Preetida J. Bhetariya, Aleksandra Markovets, Yuri Rukazenkov, (unknown), Roy S. Herbst, Masahiro Tsuboi, Yi‐Long Wu	15
3	Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations 2024 ·Clinical Cancer Research ·Ursula Grazini, Aleksandra Markovets, Lucy Ireland, Daniel O’Neill, (unknown), (unknown), Matthias Pfeifer, Tereza Vaclová, Matthew J. Martin, Ludovic Bigot, Luc Friboulet, Ryan J. Hartmaier, Maria Emanuela Cuomo, Simon T. Barry, Paul D. Smith, Nicolas Floc’h	12
4	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer breakdown → 2023 ·Nature Communications ·Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, (unknown), Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam	130
5	Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial breakdown → 2023 ·Nature Communications ·Juliann Chmielecki, Tony Mok, Yi‐Long Wu, Ji‐Youn Han, Myung‐Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih‐Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki A. Papadimitrakopoulou	95
6	Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON breakdown → 2022 ·Cancer Discovery ·Ryan J. Hartmaier, Aleksandra Markovets, Myung‐Ju Ahn, Lecia V. Sequist, Ji‐Youn Han, Byoung Chul Cho, Helena A. Yu, Sang‐We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, С. В. Орлов, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne	95
7	Osimertinib plus Selumetinib in EGFR -Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B) 2022 ·Clinical Cancer Research ·James Chih‐Hsin Yang, Yuichiro Ohe, Chao‐Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Jänne, Ryan J. Hartmaier, Myung‐Ju Ahn	10
8	A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer 2020 ·Investigational New Drugs ·Jin‐Ji Yang, Jian Fang, Yongqian Shu, Jianhua Chang, Gongyan Chen, (unknown), Wěi Li, Xiaoqing Liu, Nong Yang, Caicun Zhou, Jian Huang, Melanie M. Frigault, Ryan J. Hartmaier, (unknown), Coumaran Égile, Shethah Morgan, Remy B. Verheijen, Anders Mellemgaard, Liu Yang, Yi‐Long Wu	43
9	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype 2019 ·npj Breast Cancer ·Kevin M. Levine, Nolan Priedigkeit, Ahmed Basudan, Nilgun Tasdemir, Matthew J. Sikora, Ethan S. Sokol, Ryan J. Hartmaier, Kai Ding, (unknown), Rebecca Watters, Kurt R. Weiss, Jens‐Uwe Blohmer, Carsten Denkert, (unknown), Maria Margarete Karsten, M.M. Boisen, Esther Elishaev, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich	41
10	Targeted mutation detection in breast cancer using MammaSeq™ 2019 ·Breast Cancer Research ·(unknown), Rekha Gyanchandani, (unknown), Grzegorz T. Gurda, Peter C. Lucas, Ryan J. Hartmaier, Adam Brufsky, Shannon Puhalla, Amir Bahreini, (unknown), Abigail I. Wald, Yuri E. Nikiforov, Marina N. Nikiforova, Steffi Oesterreich, Adrian V. Lee	22
11	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers breakdown → 2018 ·Clinical Cancer Research ·Nikita Pozdeyev, Laurie M. Gay, Ethan Sokol, Ryan J. Hartmaier, Kelsi E. Deaver, Stephanie Davis, Jena D. French, Pierre Vanden Borre, Daniel V. LaBarbera, Aik Choon Tan, Rebecca E. Schweppe, Lauren Fishbein, Jeffrey S. Ross, Bryan R. Haugen, Daniel W. Bowles	374
12	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer 2018 ·Molecular Cancer Research ·Ahmed Basudan, Nolan Priedigkeit, Ryan J. Hartmaier, Ethan S. Sokol, Amir Bahreini, Rebecca Watters, M.M. Boisen, Rohit Bhargava, Kurt R. Weiss, Maria Margarete Karsten, Carsten Denkert, Jens‐Uwe Blohmer, José Pablo Leone, Ronald L. Hamilton, Adam Brufsky, Esther Elishaev, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich	24
13	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis 2017 ·Cancer Research ·Ryan J. Hartmaier, Lee A. Albacker, Juliann Chmielecki, Mark Bailey, Jie He, Michael E. Goldberg, Shakti Ramkissoon, James Suh, Julia A. Elvin, (unknown), Garrett M. Frampton, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, Doron Lipson	85
14	CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study 2017 ·Breast Cancer Research and Treatment ·Daniel L. Hertz, Kelley M. Kidwell, Susan G. Hilsenbeck, Steffi Oesterreich, C. Kent Osborne, Santosh Philips, C. Brandon Chenault, Ryan J. Hartmaier, Todd C. Skaar, Matthew J. Sikora, James M. Rae	23
15	Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring anSTK11variant 2017 ·Molecular Case Studies ·Christine A. Parachoniak, Andrew Rankin, (unknown), Ryan J. Hartmaier, (unknown), Rachel Erlich, Vincent A. Miller, Deborah Morosini, Phil Stephens, Jeffrey S. Ross, John A. Keech, Juliann Chmielecki	19
16	Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies 2017 ·Genome Medicine ·Ryan J. Hartmaier, Jehad Charo, David Fabrizio, Michael E. Goldberg, Lee A. Albacker, William Pao, Juliann Chmielecki	42
17	Steroid receptor coactivator-1 can regulate osteoblastogenesis independently of estrogen 2017 ·Molecular and Cellular Endocrinology ·Rebecca Watters, Ryan J. Hartmaier, Hatice U. Osmanbeyoglu, (unknown), James M. Rae, Lan Liao, Ke Chen, (unknown), Xinghua Lu, Steffi Oesterreich	1
18	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases 2016 ·JAMA Oncology ·Nolan Priedigkeit, Ryan J. Hartmaier, Yijing Chen, Damir Varešlija, Ahmed Basudan, Rebecca Watters, Roby Thomas, José Pablo Leone, Peter C. Lucas, Rohit Bhargava, Ronald L. Hamilton, Juliann Chmielecki, Shannon L. Puhalla, Nancy E. Davidson, Steffi Oesterreich, Adam Brufsky, Leonie S. Young, Adrian V. Lee	118
19	Novel Modeling of Combinatorial miRNA Targeting Identifies SNP with Potential Role in Bone Density 2012 ·PLoS Computational Biology ·Claudia Coronnello, Ryan J. Hartmaier, Arshi Arora, Luai Huleihel, Kusum Pandit, Abha Bais, Michael Butterworth, Naftali Kaminski, Gary D. Stormo, Steffi Oesterreich, Panayiotis V. Benos	31
20	Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients 2011 ·Clinical Cancer Research ·Thushangi N. Pathiraja, Priya B. Shetty, Jaroslav Jelı́nek, Rong He, Ryan J. Hartmaier, (unknown), Susan G. Hilsenbeck, Jean‐Pierre J. Issa, Steffi Oesterreich	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact